Growth Metrics

Sarepta Therapeutics (SRPT) R&D In Process (2019)

Sarepta Therapeutics has reported R&D In Process over the past 5 years, most recently at $173.2 million for Q2 2019.

  • Quarterly results put R&D In Process at $173.2 million for Q2 2019, changed N/A from a year ago — trailing twelve months through Dec 2019 was $232.2 million (changed N/A YoY), and the annual figure for FY2019 was $173.2 million, changed.
  • R&D In Process for Q2 2019 was $173.2 million at Sarepta Therapeutics, up from $29.5 million in the prior quarter.
  • Over the last five years, R&D In Process for SRPT hit a ceiling of $173.2 million in Q2 2019 and a floor of $173.2 million in Q2 2019.